Peptides for Hair Loss: What the Evidence Shows for Thinning Hair

Key Takeaways

• Compounds covered: GHK-Cu (copper peptide), thymosin beta-4 (TB-500), palmitoyl tetrapeptide-20, AHK-Cu, K(D)PT (alpha-MSH analog)
• Goal area: Hair loss reduction and follicle regeneration — androgenetic alopecia and telogen effluvium
• Evidence range: Ranges from controlled cosmetic studies (biomimetic peptide topicals, GHK-Cu combinations) to preclinical-only data (thymosin beta-4, AHK-Cu, K(D)PT)
• Regulatory range: Includes cosmetic ingredients (no prescription needed), and compounds with no legal prescribing or compounding pathway in the US
• Key biomarkers for hair loss: Ferritin, total testosterone, free testosterone, SHBG, TSH, hs-CRP
• As of April 2026: No peptide drug is FDA-approved for hair loss in any form. Topical GHK-Cu and AHK-Cu are regulated as cosmetic ingredients. Injectable GHK-Cu is not eligible for 503A compounding in the United States; in April 2026, FDA removed injectable GHK-Cu from its interim Category 2 list without placing it on Category 1, and Category 2 status did not authorize 503A compounding. TB-500 is not on the FDA 503A bulks list and is not eligible for compounding.
• Important: FDA-approved hair loss treatments (minoxidil, finasteride, dutasteride) are not peptides. Minoxidil is a pyrimidine derivative; finasteride and dutasteride are 5-alpha-reductase inhibitors (small molecules).
• Bottom line: One biomimetic topical peptide cosmetic has published RCT-level evidence; injectable peptides for this use have no legal compounding pathway and no published RCT.

Understanding Hair Loss: The Biology

Hair follicle cycling is the biological framework that makes peptide intervention conceptually relevant to hair loss. Each follicle passes through three phases: anagen (active growth, lasting 2–7 years), catagen (regression, approximately 2 weeks), and telogen (resting, approximately 3 months) before shedding and restarting the cycle. Stenn and Paus, in their authoritative 2001 review in Physiological Reviews, established that follicle cycling is governed by stem cell niches in the bulge region of the hair follicle, with molecular switches — including Wnt signaling, growth factors, and inflammatory mediators — controlling phase transitions.

Two types of hair loss dominate the clinical landscape. Androgenetic alopecia (AGA) is the most common form, driven by genetic susceptibility to dihydrotestosterone (DHT), which binds androgen receptors in dermal papilla cells and progressively miniaturizes the follicle until it can no longer produce a visible hair shaft. The microenvironment surrounding miniaturizing follicles is characterized by elevated inflammatory cytokines, reduced angiogenesis, and disrupted extracellular matrix signaling — each of which represents a potential peptide intervention target.

Telogen effluvium (TE) is a diffuse shedding pattern triggered when a physiological stressor — nutritional deficiency, illness, hormonal shift, or severe stress — pushes an abnormally large percentage of follicles into the telogen phase simultaneously. The StatPearls chapter by Hughes, Syed, and Saleh characterizes the pathophysiology as a premature telogen shift, with recovery typically following removal of the trigger. Hawkshaw and colleagues, writing in the British Journal of Dermatology in 2020, described Wnt pathway activation as the molecular switch governing the telogen-to-anagen transition — the exact step that several peptides under study appear to target.

Peptides are relevant to hair biology because they can interact directly with the signaling pathways that govern follicle cycling, follicle stem cell activation, dermal papilla cell proliferation, and the inflammatory microenvironment. Whether any specific peptide does so reliably in humans is a question answered compound by compound.

Peptides Studied for Hair Loss: A Quick Comparison

The following peptides have published evidence relevant to androgenetic alopecia, telogen effluvium, or follicle biology broadly. They are listed by strength of clinical evidence, from most-studied to least.

• Compound: GHK-Cu (glycine-histidine-lysine copper complex)
  Mechanism (preclinical): In preclinical models, reported to modulate follicular inflammation and extracellular matrix remodeling; proposed to act on follicle stem cells; anti-inflammatory activity in the scalp microenvironment
  Evidence: Controlled topical cosmetic studies; ex vivo hair follicle elongation data (primarily from AHK-Cu); recent combination tattooing study (Kuceki et al. 2025 — peptide's independent effect not isolable)
  FDA status: Not FDA-approved for any indication. Topical GHK-Cu is regulated as a cosmetic ingredient under FDA cosmetics law. Injectable GHK-Cu is not on the FDA 503A bulks list and is not eligible for 503A compounding. In April 2026, FDA removed injectable GHK-Cu from its interim Category 2 list without placing it on Category 1; Category 2 status did not authorize 503A compounding.
  SP availability: Not offered through Superpower for any indication
  Route: Topical (cosmetic) only
• Compound: Palmitoyl tetrapeptide-20 (alpha-MSH biomimetic)
  Mechanism (proposed): Designed to agonize melanocortin receptors in follicle microenvironment; proposed to modulate scalp immune response and reduce shedding via immunomodulatory pathway
  Evidence: Controlled clinical evidence for hair-density or shedding endpoints in humans is limited for palmitoyl tetrapeptide-20 specifically
  FDA status: Cosmetic ingredient; not FDA-approved as a drug
  SP availability: Not offered through Superpower for any indication (cosmetic ingredient only)
  Route: Topical
• Compound: Thymosin beta-4 (TB-500)
  Mechanism (preclinical): Proposed in animal models to activate quiescent follicle stem cells in the bulge region and to promote the telogen-to-anagen transition via actin dynamics and cell migration
  Evidence: Animal studies and in vitro; no completed human hair growth trials
  FDA status: Not FDA-approved for any indication. Not on the FDA 503A bulks list, has no USP-NF monograph, and is not a component of any FDA-approved drug — not eligible for 503A compounding.
  SP availability: Not offered through Superpower for any indication
  Route: Research context only
• Compound: AHK-Cu (alanine-histidine-lysine copper complex)
  Mechanism (preclinical): Reported to stimulate dermal papilla cell proliferation and hair follicle elongation ex vivo; copper complex activates follicle growth in organ culture
  Evidence: Ex vivo (human follicle organ culture) only
  FDA status: Not FDA-approved; cosmetic ingredient in some topical formulations
  SP availability: Not offered through Superpower for any indication
  Route: Topical
• Compound: K(D)PT (alpha-MSH-derived tripeptide)
  Mechanism (preclinical): In vitro studies describe effects on melanocyte activity and pigment production under inflammatory conditions; reported anti-inflammatory effects in the follicular microenvironment
  Evidence: In vitro (human hair follicle model under proinflammatory conditions)
  FDA status: Not FDA-approved; research context only
  SP availability: Not offered through Superpower for any indication
  Route: Research context only

Compounds listed as research-context or cosmetic ingredients are not legally available as prescription drugs in the US. Their inclusion here is for educational context only.

Peptides Studied for Hair Loss: Individual Profiles

Each compound targets hair biology through a distinct mechanism. Different evidence bases, different regulatory statuses, and different delivery requirements mean each requires its own evaluation — they are not interchangeable.

GHK-Cu (copper peptide)

GHK-Cu is an endogenous tripeptide-copper complex — glycine-histidine-lysine chelated to copper(II) — found in human plasma, saliva, and urine. For hair loss, GHK-Cu's proposed mechanism operates through two intersecting preclinical pathways: modulation of the inflammatory microenvironment associated with follicle miniaturization in androgenetic alopecia, and proposed effects on follicle stem cell activity and extracellular matrix remodeling. Pickart and Margolina, writing in the International Journal of Molecular Sciences in 2018, documented GHK-Cu's regenerative and anti-inflammatory actions in preclinical models, noting its role in activating tissue remodeling pathways relevant to follicular biology. Pickart and colleagues' 2015 BioMed Research International review characterized GHK as a modulator of anti-inflammatory gene expression across multiple cellular pathways in skin regeneration. Pyo and colleagues, in a 2007 Archives of Pharmacal Research study, reported that a tripeptide-copper complex stimulates human hair follicle elongation ex vivo and dermal papilla cell proliferation, providing cellular-level evidence that copper-peptide complexes can act on the dermal papilla cells and follicle structures that are miniaturized in androgenetic alopecia. Note the tested compound was a tripeptide-copper complex of the GHK-Cu family, structurally related to GHK-Cu.

Kuceki and colleagues, writing in JAAD International in 2025, evaluated a combination tattooing procedure using minoxidil, dutasteride, and a copper peptide; the combination arm showed greater AI-assessed hair regrowth than comparator monotherapy arms. The combined-delivery study design does not isolate the copper peptide's independent contribution. A separate 2025 paper by Gold and colleagues in the Journal of Cosmetic and Laser Therapy reported that a biomimetic peptide solution was studied as graft-storage media in FUE transplantation, supporting follicle viability in the graft-storage context.

Delivery method matters substantially. Li and colleagues, in a 2015 Pharmaceutical Research paper, demonstrated that polymeric microneedle pretreatment substantially enhanced GHK-Cu permeation across in vitro human skin models versus intact skin — a finding relevant to whether topical application without a delivery enhancement system reaches the target tissue. [Controlled cosmetic topical studies; preclinical follicle delivery research] GHK-Cu is not FDA-approved for hair loss. In topical cosmetic formulations, it is an over-the-counter cosmetic ingredient regulated under FDA cosmetics law. Injectable GHK-Cu is not on the FDA 503A bulks list and is not eligible for 503A compounding in the United States. In April 2026, FDA removed injectable GHK-Cu from its interim Category 2 list without placing it on Category 1; Category 2 status did not authorize 503A compounding. Injectable GHK-Cu is not available through Superpower.

Palmitoyl tetrapeptide-20 (alpha-MSH biomimetic)

Palmitoyl tetrapeptide-20 is a lipopeptide designed to mimic alpha-melanocyte-stimulating hormone (alpha-MSH), a key immunomodulatory neuropeptide in the skin. Catania and colleagues, writing in Trends in Endocrinology and Metabolism in 2000, established alpha-MSH's immunomodulatory role in normal human skin physiology, providing the mechanistic rationale for biomimetics targeting this pathway in inflammatory-driven hair loss.

Palmitoyl tetrapeptide-20 is a cosmetic α-MSH-mimetic peptide that has been investigated for scalp and hair follicle applications; controlled clinical evidence for hair-density or shedding endpoints in humans is limited. Rinaldi and colleagues published a 2019 randomized controlled study in the Journal of Dermatological Treatment of a topical cosmetic formulation containing biomimetic peptides designed by its developer to mimic growth-factor signals found in PRP, reporting measurable hair-density outcomes in the tested participant population. That is a single-product result and does not generalize to biomimetic peptides as a class. [Controlled cosmetic studies] Palmitoyl tetrapeptide-20 is regulated as a cosmetic ingredient, not a drug. It is available in over-the-counter formulations and does not require a prescription.

Thymosin beta-4 (TB-500)

Thymosin beta-4 (Tβ4) is a 43-amino-acid endogenous peptide with roles in actin cytoskeletal dynamics, cell migration, and tissue repair. For hair biology, the proposed mechanism centers on stem cell activation in the follicle bulge. Philp and colleagues, in a landmark 2004 FASEB Journal study, demonstrated that thymosin beta-4 increases hair growth by activating follicle stem cells and initiating the telogen-to-anagen transition in mice. Philp and colleagues, writing in the Annals of the New York Academy of Sciences in 2007, provided mechanistic detail on how Tβ4 mobilizes quiescent stem cells through upregulation of adhesion molecules. Dai and colleagues, in a 2021 Journal of Cellular and Molecular Medicine review, characterized multiple roles of thymosin β4 across hair cycle phases, including angiogenesis and extracellular matrix remodeling contributions.

This preclinical evidence is biologically interesting. However, no completed human randomized controlled trial of TB-500 for hair loss has been published. [Animal studies / in vitro only for hair loss indication] Thymosin beta-4 and TB-500 are not FDA-approved for any indication. TB-500 is not on the FDA 503A bulks list, has no USP-NF monograph, and is not a component of any FDA-approved drug. Under Section 503A, TB-500 is therefore not eligible for compounding in the United States — for any indication. It has no lawful prescribing or compounding pathway. TB-500 is not prescribed, compounded, or dispensed through Superpower.

AHK-Cu and K(D)PT

AHK-Cu (alanine-histidine-lysine copper complex) is a structural analog of GHK-Cu with potentially enhanced dermal papilla cell-stimulating properties. Pyo and colleagues, in their 2007 ex vivo study, demonstrated that a tripeptide-copper complex stimulates human hair follicle elongation and dermal papilla cell proliferation in organ culture — cellular-level evidence that the compound acts on the specific cell type responsible for follicle growth regulation. [In vitro / ex vivo only]

K(D)PT is an alpha-MSH-derived tripeptide incorporating a D-lysine substitution for protease resistance. Meyer and colleagues, in a 2009 British Journal of Dermatology study, reported that K(D)PT stimulates human hair follicle pigmentation and melanocyte activity in vitro under proinflammatory conditions. This positions it as potentially relevant to premature graying in research contexts; the cited paper evaluates pigmentation endpoints rather than hair density or shedding, so the evidence does not extend to clinical hair loss outcomes. [In vitro only] Neither AHK-Cu nor K(D)PT is FDA-approved for any indication. K(D)PT is not on the 503A bulks list, is not on the 503B clinical need list, and has no lawful compounding or prescribing pathway in the United States.

Regulatory Status at a Glance

As of April 2026, the peptides discussed in this article carry different regulatory statuses. These distinctions matter when discussing any of them with a healthcare provider.

• GHK-Cu (topical cosmetic formulations): Cosmetic ingredient regulated under FDA cosmetics law (21 U.S.C. § 361); not evaluated or approved to diagnose, treat, cure, or prevent any disease
• GHK-Cu (injectable): Not FDA-approved for any indication. Injectable GHK-Cu is not on the FDA 503A bulks list, has no USP-NF monograph, and is not a component of an FDA-approved drug; it is not eligible for 503A compounding and has no legal prescribing or dispensing pathway in the United States. In April 2026, FDA removed injectable GHK-Cu from its interim Category 2 bulks list without placing it on Category 1; Category 2 status did not authorize 503A compounding. Not available through Superpower.
• Palmitoyl tetrapeptide-20: Cosmetic ingredient; over-the-counter availability; not FDA-approved as a drug
• Thymosin beta-4 (TB-500): Not FDA-approved for any indication. Not on the FDA 503A bulks list; no USP-NF monograph; not a component of any FDA-approved drug. Under Section 503A, TB-500 is not eligible for compounding in the United States. Not available through Superpower.
• AHK-Cu (topical cosmetic formulations): Cosmetic ingredient regulated under FDA cosmetics law; not FDA-approved as a drug. Injectable AHK-Cu is not on the FDA 503A bulks list and is not eligible for 503A compounding.
• K(D)PT: Not FDA-approved; not on the 503A bulks list; not on the 503B clinical need list; no lawful compounding or prescribing pathway in the United States
• Minoxidil and finasteride (non-peptides): FDA-approved treatments for androgenetic alopecia in the United States. Minoxidil is a pyrimidine derivative (small molecule); finasteride is a 5-alpha-reductase inhibitor. Dutasteride is FDA-approved for benign prostatic hyperplasia and is used off-label for androgenetic alopecia in the US. None is a peptide.

Important: As of April 2026, there is no FDA-approved peptide drug for hair loss or hair growth, for any form of alopecia. The FDA-approved treatments for androgenetic alopecia in the United States — topical and oral minoxidil, and finasteride — are not peptides. Minoxidil is a pyrimidine derivative; finasteride is a 5-alpha-reductase inhibitor. Dutasteride is FDA-approved for benign prostatic hyperplasia and is used off-label for androgenetic alopecia; it is also a 5-alpha-reductase inhibitor and not a peptide. These non-peptide drugs are referenced in this article for evidence-base comparison only.

Considerations When Comparing Peptides for Hair Loss

Comparing peptides for hair loss requires a clinically grounded framework — not a ranked list. The compounds above have been studied in different populations, using different endpoints, and with different delivery methods. Inferring relative effectiveness from separate studies is methodologically unreliable.

Your specific type of hair loss: Androgenetic alopecia, telogen effluvium, alopecia areata, and other causes have distinct mechanisms. A compound with evidence for one type does not necessarily transfer to another. A provider-led differential diagnosis is the necessary starting point.

Existing biomarker profile: Elevated androgens, low ferritin, thyroid dysfunction, and elevated inflammatory markers each suggest different underlying drivers. The compounds that are mechanistically relevant to one driver — say, GHK-Cu for inflammatory-driven AGA — are not the same as those relevant to another, such as nutritional correction for iron-deficiency TE.

Evidence level comfort: Topical cosmetic peptides (palmitoyl tetrapeptide-20, GHK-Cu) have the best clinical evidence currently available. Injectable compounds have compelling preclinical rationale but far less human data for hair loss specifically. Providers will weigh this when discussing options.

Delivery route and practical access: Topical cosmetic formulations are OTC and require no prescription. Injectable GHK-Cu is not on the FDA 503A bulks list and is not eligible for 503A compounding. TB-500 is not on the FDA 503A bulks list and has no legal compounding pathway.

Regulatory status of the compound: The distinction between a cosmetic ingredient, a compounded prescription compound, and a research-only peptide affects both legal access and the informed consent process.

This is not an exhaustive list of clinical considerations. A licensed provider — ideally a dermatologist with experience in hair loss — will evaluate your hair loss type, medical history, and baseline labs before recommending any compound.

Safety Considerations

Safety profiles across this compound class are not uniform. Topical cosmetic peptides such as palmitoyl tetrapeptide-20 and GHK-Cu in cosmetic formulations have been used at cosmetic-ingredient doses with a generally well-tolerated profile; however, these are not formally evaluated drug products. Injectable forms — including GHK-Cu injectable and TB-500 — currently have no legal compounding pathway in the US. Historically, injectable copper-peptide use has carried the standard risks associated with any subcutaneous injection: injection site reactions, sterility concerns if preparation standards are not met, and unknown long-term systemic effects at the doses reported in unregulated vendor contexts.

Products sold online as injectable peptides are outside the regulated pharmacy system. Administration of unregulated injectables bypasses the safety evaluation and monitoring that a provider-directed, legally sourced injectable therapy would otherwise provide.

Contraindications that apply broadly to injectable hair loss peptide therapy include:

• Pregnancy or breastfeeding — reproductive and developmental safety data are absent for all peptides in this class
• Active hormone-sensitive malignancy — compounds that interact with androgen signaling or growth pathways carry theoretical oncologic considerations
• Known hypersensitivity to copper (for GHK-Cu) — rare but documented
• Undiagnosed diffuse hair loss without laboratory workup — treatment without distinguishing the cause creates risk of pursuing an ineffective intervention while an underlying condition goes unaddressed

For compound-specific side effect profiles, see the individual compound pages linked above.

What to Test Before Starting Peptides for Hair Loss

Regardless of which compound you and your provider discuss, baseline biomarker testing identifies the underlying biology driving hair loss. Without that data, there is no objective basis for distinguishing androgenetic alopecia from telogen effluvium from thyroid-related loss — and no way to select an appropriately targeted intervention.

• Ferritin: The most sensitive available marker for iron depletion. Low ferritin is one of the most common and correctable drivers of telogen effluvium; levels below 30 ng/mL are associated with diffuse shedding even when hemoglobin is normal. Testing ferritin separately from a standard CBC is essential — iron-deficiency TE is frequently missed when only CBC is ordered.
• Total and free testosterone: Elevated androgens or high free-to-bound testosterone ratios drive DHT-mediated follicle miniaturization in androgenetic alopecia. Testing total testosterone and free testosterone establishes whether androgen excess is contributing.
• SHBG (sex hormone-binding globulin): SHBG determines how much testosterone is biologically available. Low SHBG increases free androgen availability and can accelerate androgenetic alopecia progression even when total testosterone appears normal.
• TSH (thyroid-stimulating hormone): Both hypothyroidism and hyperthyroidism cause diffuse hair loss that can be mistaken for telogen effluvium or androgenetic alopecia. A TSH baseline rules out a common and highly treatable cause before pursuing peptide interventions.
• hs-CRP (high-sensitivity C-reactive protein): Follicular inflammation is increasingly recognized as a driver of both androgenetic alopecia and telogen effluvium recurrence. Testing hs-CRP provides an objective measure of systemic inflammatory burden that may direct providers toward anti-inflammatory compound approaches.
• Prolactin: Elevated prolactin suppresses gonadal hormone production and can trigger diffuse shedding. A prolactin baseline screens for hyperprolactinemia as a reversible hormonal driver.
• Comprehensive metabolic panel: Liver and kidney function baselines are relevant before any injectable compound, and the CMP also identifies metabolic contributors to hair loss including blood glucose dysregulation and nutritional status indicators.

Ferritin, TSH, total testosterone, free testosterone, SHBG, and hs-CRP together establish the hormonal and inflammatory context that distinguishes the most common types of hair loss. Testing at baseline before any intervention — and again at 3–6 months — provides the data needed to assess whether biology is changing in response. Superpower's hair loss panel is designed around this biomarker set.

How to Access These Peptides Safely

Topical cosmetic peptide formulations — palmitoyl tetrapeptide-20, GHK-Cu in cosmetic form — are available over the counter without a prescription. They are not regulated as drugs, are not evaluated for therapeutic efficacy by the FDA, and should be evaluated on the basis of the published cosmetic study evidence summarized above.

Injectable GHK-Cu is not on the FDA 503A bulks list and is not eligible for 503A compounding in the United States. In April 2026, FDA removed injectable GHK-Cu from its interim Category 2 list without placing it on Category 1; Category 2 status did not authorize 503A compounding. Injectable GHK-Cu is not available through Superpower. TB-500 / thymosin beta-4 is not on the FDA 503A bulks list and has no legal compounding pathway. K(D)PT is not on the 503A bulks list or 503B clinical need list.

Compounds sold online as injectable peptides outside a licensed pharmacy relationship lack pharmaceutical-grade manufacturing oversight. Purity, potency, and sterility cannot be assumed from unregulated sources. Superpower does not facilitate access to injectable GHK-Cu, TB-500, thymosin beta-4, AHK-Cu injectable, or K(D)PT for any indication.

For evaluation of hair loss: a provider consultation — typically with a dermatologist — will cover a detailed hair loss history, physical examination or trichoscopy, review of baseline laboratory markers (the set listed above), and discussion of FDA-approved (non-peptide) options. FDA-approved treatments for androgenetic alopecia in the United States are topical minoxidil (OTC) and oral finasteride (prescription); dutasteride is approved by FDA for benign prostatic hyperplasia and is used off-label for androgenetic alopecia in the US. None of these are peptides.

Understanding Your Baseline

Hair loss has multiple biological causes — hormonal, nutritional, inflammatory, thyroid-mediated — and the peptide compounds studied for it target different pathways. Baseline biomarker data transforms a clinical conversation from speculation about which compound to try toward a specific understanding of which mechanism is actually driving the loss. That specificity makes a meaningful difference in whether any intervention is likely to be useful.

That principle — test first, then decide — is central to Superpower's approach to preventive health. Whether the conversation with your provider leads to a topical cosmetic peptide, an FDA-approved treatment, or a nutritional correction based on ferritin or thyroid values, the starting point is the same: understanding what the biology actually shows.

IMPORTANT SAFETY INFORMATION

GHK-Cu (glycine-histidine-lysine copper complex) is not FDA-approved for any indication, including hair loss. Injectable GHK-Cu is not on the FDA 503A bulks list, has no USP-NF monograph, and is not a component of an FDA-approved drug; under Section 503A, it is not eligible for compounding in the United States. In April 2026, FDA additionally removed injectable GHK-Cu from its interim Category 2 bulks list without placing it on Category 1; Category 2 status did not authorize 503A compounding. Injectable GHK-Cu is not available through Superpower. GHK-Cu in topical cosmetic formulations is regulated as a cosmetic ingredient under FDA cosmetics law; cosmetic ingredients are not evaluated or approved to diagnose, treat, cure, or prevent any disease.

Thymosin beta-4 (TB-500) is not FDA-approved for any medical use. TB-500 is not on the FDA 503A bulks list, has no USP-NF monograph, and is not a component of any FDA-approved drug; under Section 503A, it is not eligible for compounding in the United States for any indication. Research on thymosin beta-4 for hair loss has been limited to animal and in vitro studies; no completed human clinical trials for this indication have been published. Its safety, efficacy, appropriate dosing, and long-term effects in humans for hair loss have not been established. Superpower does not facilitate access to thymosin beta-4 or TB-500.

Palmitoyl tetrapeptide-20 and AHK-Cu in topical cosmetic formulations are regulated as cosmetic ingredients, not drugs. Cosmetic ingredients are not evaluated or approved by the FDA to diagnose, treat, cure, or prevent any disease or medical condition. Claims about physiological effects on hair follicles beyond cosmetic appearance are not supported by FDA evaluation.

K(D)PT is not approved by the FDA for any medical use. Research has been limited to in vitro studies. It is not prescribed, compounded, or dispensed through Superpower. Its inclusion is for educational context only.

This article is not a substitute for medical advice, diagnosis, or treatment. Hair loss has multiple causes that require clinical evaluation and laboratory testing to distinguish. A licensed dermatologist or healthcare provider should evaluate any persistent hair loss before any treatment is initiated.

FDA-approved treatments for androgenetic alopecia in the United States — topical minoxidil, oral minoxidil, and finasteride — are not peptides. Dutasteride is FDA-approved for benign prostatic hyperplasia and is used off-label for androgenetic alopecia; it is not a peptide. Minoxidil is a pyrimidine derivative; finasteride and dutasteride are 5-alpha-reductase inhibitors (small molecules). These non-peptide drugs are referenced in this article for evidence-base comparison only. Full FDA-approved prescribing information for approved hair loss treatments at dailymed.nlm.nih.gov.